ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for VRAYQ. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: VRAYQ is a Buy candidate.
VRAYQ stock price ended at $0 on 星期一, after rising NaN%
On the latest trading day Mar 23, 2026, the stock price of VRAYQ rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 178 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 122 shares were traded, amounting to a market value of approximately --.